CA2377662A1 - Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase - Google Patents

Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase Download PDF

Info

Publication number
CA2377662A1
CA2377662A1 CA002377662A CA2377662A CA2377662A1 CA 2377662 A1 CA2377662 A1 CA 2377662A1 CA 002377662 A CA002377662 A CA 002377662A CA 2377662 A CA2377662 A CA 2377662A CA 2377662 A1 CA2377662 A1 CA 2377662A1
Authority
CA
Canada
Prior art keywords
seq
phosphatase
amino acid
cancer
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377662A
Other languages
English (en)
Inventor
Gregory D. Plowman
Ricardo Martinez
David Whyte
Ron Hill
Peter Flanagan
Mario Lioubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377662A1 publication Critical patent/CA2377662A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La présente invention concerne des polypeptides, des acides nucléiques codant pour ces polypeptides, des cellules, des tissus et des animaux contenant ces acides nucléiques, des anticorps contre les polypeptides, des bioanalyses dans lesquelles sont utilisés les polypeptides, et des méthodes concernant tous les éléments mentionnés ci-dessus. Les polypeptides de la présente invention sont, de préférence des phosphatases. Des éléments mammaliens de la famille des phosphatases sont présentés grâce à l'utilisation d'un script bioinformatique "d'extraction de motifs". Ces phosphatases incluent les protéines de type MKP, une protéine de type CDC14, une protéine de type PTEN, et des protéines de type myotubularine (MTM). La classification des protéines en tant qu'éléments nouveaux de familles établies s'est révélée particulièrement exacte, non seulement quant à la prévision des motifs présents dans la partie non catalytique restante de chaque protéine, mais aussi quant à leur régulation, leurs substrats, et leurs voies de signalisation.
CA002377662A 1999-08-13 2000-08-11 Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase Abandoned CA2377662A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14900599P 1999-08-13 1999-08-13
US60/149,005 1999-08-13
PCT/US2000/022158 WO2001012819A2 (fr) 1999-08-13 2000-08-11 Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase

Publications (1)

Publication Number Publication Date
CA2377662A1 true CA2377662A1 (fr) 2001-02-22

Family

ID=22528389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377662A Abandoned CA2377662A1 (fr) 1999-08-13 2000-08-11 Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase

Country Status (5)

Country Link
EP (1) EP1212433A2 (fr)
JP (1) JP2003507016A (fr)
AU (1) AU6903800A (fr)
CA (1) CA2377662A1 (fr)
WO (1) WO2001012819A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4367600A (en) * 1999-07-02 2001-01-22 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
US7504223B2 (en) * 1999-08-05 2009-03-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Knockout mouse for the tumor suppressor gene ANX7
US6420153B1 (en) * 2000-02-29 2002-07-16 Millennium Pharmaceuticals, Inc. 18232, a novel dual specificity phosphatase and uses therefor
AU2001247782A1 (en) * 2000-03-24 2001-10-08 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
EP1305404A2 (fr) * 2000-07-28 2003-05-02 Incyte Genomics, Inc. Proteines phosphatases
WO2002020732A2 (fr) * 2000-09-07 2002-03-14 Bayer Aktiengesellschaft Régulation d'enzyme humaine de type map kinase phosphatase
WO2002020747A2 (fr) * 2000-09-11 2002-03-14 Bayer Aktiengesellschaft Regulation de l'enzyme humaine du type tyrosine phosphatase
US6825021B2 (en) 2000-09-19 2004-11-30 Ceptyr, Inc. DSP-15 dual-specificity phosphatase
CA2398924A1 (fr) * 2000-11-20 2002-05-30 Pe Corporation (Ny) Proteines phosphatases humaines et molecules d'acide nucleique isolees, codant des proteines phosphatases humaines, et leurs utilisations
US7153678B2 (en) 2000-12-20 2006-12-26 Bristol-Myers Squibb Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
EP1387889A2 (fr) * 2001-01-18 2004-02-11 Incyte Genomics, Inc. Kinases et phosphatases
WO2003038118A1 (fr) * 2001-10-31 2003-05-08 Fujisawa Pharmaceutical Co., Ltd. Methode d'evaluation d'inhibiteurs de la phosphatase
US20030148341A1 (en) * 2001-11-15 2003-08-07 Sin Wun Chey Gene amplification and overexpression in cancer
WO2003083102A2 (fr) * 2002-03-28 2003-10-09 Qlt Inc. Proteines phosphatases associees au cancer et leurs utilisations
WO2004028554A2 (fr) * 2002-09-27 2004-04-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines skrp, astray, string, vacm associees a la regulation metabolique
JP2010535503A (ja) 2007-08-10 2010-11-25 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ（エー＊エスティーエーアール） 癌の診断および治療のためのｖｈｚ
CN102176914B (zh) 2008-08-08 2014-12-17 新加坡科技研究局 用于诊断和治疗癌症的vhz

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002704A2 (fr) * 1997-07-08 1999-01-21 Cold Spring Harbor Laboratory Phosphatase a double specificite et procedes d'utilisation
WO2000006728A2 (fr) * 1998-07-28 2000-02-10 Incyte Pharmaceuticals, Inc. Effecteurs de phosphorylation
WO2000018890A2 (fr) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Nouvelles molecules de proteine phosphatase et utilisation de ces molecules
EP1192257A2 (fr) * 1999-03-18 2002-04-03 Incyte Pharmaceuticals, Inc. Regulateur de la phosphorylation intracellulaire
US6852520B1 (en) * 1999-03-24 2005-02-08 Ceptyr, Inc. DSP-2 dual-specificity phosphatase
CA2367104A1 (fr) * 1999-04-07 2000-10-12 Ceptyr, Inc. Map kinase phosphatase a double specificite dsp-7
EP1171614A1 (fr) * 1999-04-07 2002-01-16 Ceptyr, Inc. Map kinase phosphatase a double specificite dsp-4
AU4470200A (en) * 1999-04-20 2000-11-02 Ceptyr, Inc. Dsp-8 dual-specificity map kinase phosphatase
EP1173587A1 (fr) * 1999-04-23 2002-01-23 Ceptyr, Inc. Kinase phosphatase dsp-10 a double specificite activee par un mitogene
US6645753B1 (en) * 1999-04-27 2003-11-11 Ceptyr, Inc. DSP-5 dual-specificity phosphatase
AU4367600A (en) * 1999-07-02 2001-01-22 Ceptyr, Inc. Dsp-3 dual-specificity phosphatase
EP1200602A1 (fr) * 1999-07-20 2002-05-02 Ceptyr, Inc. Phosphatase kinase map a specificite duale dsp-11
JP2003509053A (ja) * 1999-09-15 2003-03-11 インサイト・ゲノミックス・インコーポレイテッド プロテインホスファターゼ及びプロテインキナーゼ

Also Published As

Publication number Publication date
WO2001012819A2 (fr) 2001-02-22
JP2003507016A (ja) 2003-02-25
EP1212433A2 (fr) 2002-06-12
WO2001012819A3 (fr) 2002-01-24
AU6903800A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
EP1073723B1 (fr) Proteines kinases apparentees a la famille de ste20
US20060234344A1 (en) Protein kinases
US20070202107A1 (en) Novel kinases
US20050125852A1 (en) Novel kinases
CA2377662A1 (fr) Nouvelles phosphatases de proteines et diagnostic et traitement des troubles lies a la phosphatase
JP2003517836A (ja) 哺乳動物蛋白質ホスファターゼ
US20060292573A1 (en) Human orthologues of WART
US20080009610A1 (en) Diagnosis and treatment of PTP related disorders
CA2331889A1 (fr) Kinases en rapport avec nek et avec bub1
US20040157306A1 (en) Mammalian protein phosphatases
US6844177B2 (en) Diagnosis and treatment of PTP04 related disorders
US20040132155A1 (en) Mammalian protein phosphatases
US20020090703A1 (en) Mammalian protein phosphatases
US7029912B1 (en) Tyrosine kinase substrate(Tks) proteins
US20050084877A1 (en) Mammalian protein phosphatases
US6342593B1 (en) Diagnosis and treatment of ALP related disorders
CA2362943A1 (fr) Proteines fixatrices pyk2
WO1999027099A1 (fr) Substrat 'orf' pour kinase 'erk-6' regulee par signaux extracellulaires, et procedes correspondants
CA2395093A1 (fr) Proteines phosphatases mammiferes
CA2365623A1 (fr) Proteines de substrats de tyrosines kinases (tks)
EP1299525A2 (fr) Proteines phosphatases mammiferes

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060811